Manufacturing, Gene Therapies

Andelyn Biosciences Opens New CGT Manufacturing Headquarters

June 22, 2023

The new headquarters located in Columbus, Ohio, more than triples Andelyn Biosciences’ footprint to meet growing demand for CGT services.

Vinnova Supports the Formation of Nordic CCRM Hub

May 31, 2023

The project is being coordinated by the recently formed not-for-profit CCRM Nordic AB and gathers engaged stakeholders to move the initiative forward.

CATTI Starts Up CGT Training Center at University of Guelph

May 17, 2023

CATTI has launched an in-person training site at the University of Guelph in Ontario, Canada, for training personnel in cell and gene therapy manufacturing.

Exothera Partners with Remedium to Scale-Up Manufacturing of Gene Therapy Drug Candidate

March 30, 2023

CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.

TrakCel and Lonza Reach Integration Milestone to Combine Cell and Gene Therapy Manufacturing, Orchestration Solutions

March 22, 2023

The combined solutions are currently available on the market.

Sartorius and Teknova Team Up for Gene Therapy Process Development

March 21, 2023

Sartorius BIA Separations and Teknova will collaborate to combine their technologies in an effort to streamline the downstream purification process.

Catalent Expands UpTempo AAV Platform

March 09, 2023

Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.

Advances in In Vivo CAR T-cell Therapies

March 01, 2023

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.

AbbVie and Capsida Strike $674 Million Gene Therapy Development Deal

February 24, 2023

AbbVie and Capsida have expanded their existing collaboration to advance three new gene therapy programs.

The Center for Breakthrough Medicines Announces Plasmid Manufacturing Service

February 07, 2023

CBM’s plasmid manufacturing offering is designed to provide phase-appropriate plasmids on demand for companies working on cell and gene therapies.